OM:CAMXPharmaceuticals
Camurus (OM:CAMX) Valuation Check After New Long‑Acting Hypoparathyroidism Collaboration with Gubra
Camurus (OM:CAMX) just signed an exclusive collaboration and license deal with Danish biotech Gubra to develop a long acting treatment for hypoparathyroidism, a move that could quietly reshape its long term growth story.
See our latest analysis for Camurus.
The market seems to be pausing to reassess Camurus after a strong multi year run. The 90 day share price return of negative 13.19 percent contrasts with an impressive five year total shareholder return of 223.11 percent, suggesting long...